Last reviewed · How we verify

Combined Depo-Medrone and Lidocaine

Barts & The London NHS Trust · FDA-approved active Small molecule Quality 0/100

Combined Depo-Medrone and Lidocaine is a Small molecule drug developed by Barts & The London NHS Trust. It is currently FDA-approved. Also known as: Methylprednisolone Acetate BP 40mg/mL:, Lidocaine Hydrochloride 2%:.

At a glance

Generic nameCombined Depo-Medrone and Lidocaine
Also known asMethylprednisolone Acetate BP 40mg/mL:, Lidocaine Hydrochloride 2%:
SponsorBarts & The London NHS Trust
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Combined Depo-Medrone and Lidocaine

What is Combined Depo-Medrone and Lidocaine?

Combined Depo-Medrone and Lidocaine is a Small molecule drug developed by Barts & The London NHS Trust.

Who makes Combined Depo-Medrone and Lidocaine?

Combined Depo-Medrone and Lidocaine is developed and marketed by Barts & The London NHS Trust (see full Barts & The London NHS Trust pipeline at /company/barts-the-london-nhs-trust).

Is Combined Depo-Medrone and Lidocaine also known as anything else?

Combined Depo-Medrone and Lidocaine is also known as Methylprednisolone Acetate BP 40mg/mL:, Lidocaine Hydrochloride 2%:.

What development phase is Combined Depo-Medrone and Lidocaine in?

Combined Depo-Medrone and Lidocaine is FDA-approved (marketed).

Related